Nightstar Therapeutics to Present at Wedbush PacGrow Healthcare Conference
07 August 2018 - 8:05PM
Nightstar Therapeutics plc (NASDAQ: NITE), a clinical-stage gene
therapy company developing treatments for rare inherited retinal
diseases, today announced that the company plans on presenting at
the 2018 Wedbush PacGrow Healthcare Conference on Tuesday, August
14, 2018 at 12:45 p.m. ET in New York City.
To access the live webcast, please visit ir.nightstartx.com. A
replay of the webcast will be available on the Nightstar website
for two weeks following the conference.
About Nightstar
Nightstar is a leading clinical-stage gene therapy company
focused on developing and commercializing novel one-time treatments
for patients suffering from rare inherited retinal diseases that
would otherwise progress to blindness. Nightstar’s lead product
candidate, NSR-REP1, is currently in Phase 3 development for the
treatment of patients with choroideremia, a rare, degenerative,
genetic retinal disorder that has no current treatments. Results
from a Phase 1/2 trial of NSR-REP1 were published in The Lancet in
2014 and in The New England Journal of Medicine in 2016.
Nightstar’s second product candidate, NSR-RPGR, is currently being
evaluated in a Phase 1/2 clinical trial for the treatment of
patients with X-linked retinitis pigmentosa, an inherited X-linked
recessive retinal disease.
For more information about Nightstar or its clinical trials,
please visit www.nightstartx.com.
Contacts:Senthil Sundaram, Chief Financial
OfficerBrian Luque, Sr. Manager, Investor
Relationsinvestors@nightstartx.com
Nightstar Therapeutics Plc ADS (NASDAQ:NITE)
Historical Stock Chart
From Jun 2024 to Jul 2024
Nightstar Therapeutics Plc ADS (NASDAQ:NITE)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Nightstar Therapeutics Plc ADS (NASDAQ): 0 recent articles
More News Articles